What happens after treatment? A systematic review of relapse, remission, and recovery in anorexia nervosa.

J Eat Disord

Department of Psychiatry and Biobehavioral Sciences, The University of California Los Angeles, Semel Institute of Neuroscience and Human Behavior, 760 Westwood Plaza, Los Angeles, CA 90024 USA.

Published: June 2017

Background: Relapse after treatment for anorexia nervosa (AN) is a significant clinical problem. Given the level of chronicity, morbidity, and mortality experienced by this population, it is imperative to understand the driving forces behind apparently high relapse rates. However, there is a lack of consensus in the field on an operational definition of relapse, which hinders precise and reliable estimates of the severity of this issue. The primary goal of this paper was to review prior studies of AN addressing definitions of relapse, as well as relapse rates.

Methods: Data sources included PubMed and PsychINFO through March 19th, 2016. A systematic review was performed following the PRISMA guidelines. A total of ( = 27) peer-reviewed English language studies addressing relapse, remission, and recovery in AN were included.

Results: Definitions of relapse in AN as well as definitions of remission or recovery, on which relapse is predicated, varied substantially in the literature. Reported relapse rates ranged between 9 and 52%, and tended to increase with increasing duration of follow-up. There was consensus that risk for relapse in persons with AN is especially high within the first year following treatment.

Discussion: Standardized definitions of relapse, as well as remission and recovery, are needed in AN to accelerate clinical and research progress. This should improve the ability of future longitudinal studies to identify clinical, demographic, and biological characteristics in AN that predict relapse versus resilience, and to comparatively evaluate relapse prevention strategies. We propose standardized criteria for relapse, remission, and recovery, for further consideration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470198PMC
http://dx.doi.org/10.1186/s40337-017-0145-3DOI Listing

Publication Analysis

Top Keywords

remission recovery
20
relapse
15
relapse remission
12
definitions relapse
12
relapse well
12
systematic review
8
anorexia nervosa
8
relapse rates
8
studies addressing
8
remission
5

Similar Publications

[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa.].

Recenti Prog Med

January 2025

Divisione di Ematologia e terapie cellulari, Irccs Ospedale Policlinico San Martino, Genova.

CAR-T therapy (chimeric antigen receptor T-cell) has revolutionized the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) that have relapsed or are refractory to conventional chemotherapies. In particular, patients who have relapsed or are refractory to two lines of therapy are patients who have a poor prognosis. The advent of CAR-T immunotherapy is an innovative approach with which we can give hope of recovery even in the case of refractory disease, even for patients who are not candidates for high-dose therapies, for example due to age.

View Article and Find Full Text PDF

Despite 75% of people who experience a first episode of psychosis (FEP) reaching clinical remission, this population continue to face lower rates of vocational recovery. This review aimed to identify the factors which help and hinder individuals' employment and post-secondary education engagement post-FEP. Three electronic databases (Psych INFO, Medline and Social Science Database) were searched up to 21st August 2023.

View Article and Find Full Text PDF

Objective: The aim of the study was to investigate the therapeutic effects of modified electroconvulsive therapy (MECT) in combination with risperidone tablets and psychotherapy in the treatment of patients with treatment-resistant schizophrenia (TRS).

Methods: Patients with TRS admitted to the psychiatric department of our hospital between January 2018 and December 2019 were selected as study participants. They were randomly divided into a control group and a study group, with the control group receiving risperidone tablets and psychotherapy, and the study group undergoing MECT as well as the control group treatment.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: TongXieYaoFang (TXYF), a classical formula used in Traditional Chinese Medicine, is renowned for its efficacy in treating chronic abdominal pain and diarrhoea. Modern research suggests that fundamental relief from these symptoms depends on complete intestinal mucosal healing, which normalises gut secretory functions. Consensus between traditional and modern medical theories indicates that TXYF is particularly suitable for treating the remission phase of ulcerative colitis (UC).

View Article and Find Full Text PDF

Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!